# Shifting the Narrative: Trends in Stigmatizing Language and Sentiment Towards Migraine Treatments on Social Media

Teshamae S. Monteith, MD, FAHS, FAAN,<sup>1</sup> Monica Verduzco-Gutierrez, MD,<sup>2</sup> Annika Ehrlich, DNP,<sup>3</sup> Heather Moran, M.Ed.,<sup>4</sup> Nina Riggins, MD, PhD,<sup>5</sup> Amaal J. Starling, MD, FAHS, FAAN,<sup>6</sup> Meghan Fajardo, PharmD,<sup>7</sup> and Samantha Sweeney, PharmD, MBA<sup>7</sup>


<sup>1</sup>University of Miami, Miller School of Medicine, Miami, FL, USA; <sup>2</sup>Department of Rehabilitation Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; <sup>3</sup>UCSF Health, San Francisco, CA, USA; <sup>4</sup>American Migraine Foundation, New York, NY, USA; <sup>5</sup>Headache Center of Excellence, VA Palo Alto, CA, USA; <sup>6</sup>Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA; <sup>7</sup>Pfizer Inc., New York, NY, USA.

### **Disclosures**

- TSM has been an advisor to Pfizer, a sponsor for this study, over the past 3 years.
- TSM has other disclosures over the past 3 years: clinical trial site principal investigator for studies sponsored by Eli Lilly and AbbVie (all paid to the institution), participation in an advisory board/consultancy for AbbVie, Axsome, Teva, Linpharma, e-Neura, Novartis, Merz, and Lundbeck. She has received educational grants from Amgen and AbbVie, personal fees from Medscape, Massachusetts Medical Society, American Headache Society, American Academy of Neurology, AbbVie, Novartis, unpaid co-author for research funded by AbbVie, Pfizer/Biohaven, and Theranica. She is an associate editor for Cephalalgia and Continuum Audio, deputy editor for Neurology Minute, and is on the editorial board for Neurology, American Migraine Foundation, and Brain and Life Magazine. TSM has provided unpaid service on the board of directors for the International Headache Society (2021–2023) and is currently on the executive board for the Florida Society of Neurology and the American Migraine Foundation.

### Introduction


- Recent efforts have been initiated to help address the issue of psychological burden and stigma associated with migraine<sup>1,2</sup>
  - June 2019: CHAMP released a language and image guide to help reduce the use of stigmatizing language<sup>3</sup>
  - **July 2023: AMF** published recommendations for appropriate language to use in migraine advocacy<sup>4</sup>
- Coinciding with this increased focus on migraine stigma and advocacy, CGRP-targeting therapies have emerged<sup>5,6</sup>
  - These new treatments may have reshaped perceptions and experiences of people with migraine<sup>5,6</sup>





**Objective**: To understand the potential impact of both the language guidelines and the introduction of CGRP-targeting therapies by examining language use and sentiment on social media

### Methods: Lexicon Analysis on Social Media Pre- vs Postpublication of CHAMP Guidelines



### **Data Analysis**

- The number of posts with CHAMP/AMF recommended language vs discouraged legacy language was examined as a ratio
- Posts were normalized by number of posts per month:
  - Monthly average of:

# posts using CHAMP/AMF language

# posts using discouraged legacy language

AMF, American Migraine Foundation; CHAMP, Coalition for Headache and Migraine Patients; HCP, healthcare professional; SQL, structured query language.

1. CHAMP Coalition for Headache and Migraine Patients. Published online June 2019. https://headachemigraine.org/wp-content/uploads/2021/01/CHAMP\_Language\_Guide\_2019\_website.pdf


## Methods: Lexicon Analysis on Social Media Pre- vs Postpublication of CHAMP Guidelines (cont'd)

CHAMP/AMF Recommended Language Changes <sup>1,2</sup>							
Previously Used Language	Recommended Language	Category of Language					
Headache(s)	Headache Disease(s), Headache Disorder(s)	Not used in analysis due to lack of specificity in legacy language					
Headache(s), Migraine(s), Episode(s)	Headache Attack, Migraine Attack, Cluster Attack	Terms for migraine occurrence					
Migraine Headache, Migraines	Migraine Disease, Living With Migraine Disease	Terms for migraine disease					
Migraine Personality, Migraineur, Migrainer, Migraine Person, Migraine-Type Person	Person With Migraine Disease, Person Living With Migraine Disease	Terms for person with migraine disease					
Suffering From Migraine, Migraine Sufferer	Experience(s) the Pain and Disability of Migraine Disease	Terms related to the burden of migraine disease					
No Term Previously Used	Migraine Spectrum, Migraine Continuum	Not used in analysis due to lack of associated legacy language					
Cured of Migraine, Migraine Cure, Migraine Miracle	Migraine Remission, Break in Migraine Attacks	Terms for reduction in migraine attacks					
Medication Overuse Headache, Rebound Headache	Medication Adaptation Headache	Terms for medication-associated headache					

AMF, American Migraine Foundation; CHAMP, Coalition for Headache and Migraine Patients.

<sup>1.</sup> CHAMP Coalition for Headache and Migraine Patients. Published online June 2019. https://headachemigraine.org/wp-content/uploads/2021/01/CHAMP\_Language\_Guide\_2019\_website.pdf 2. American Migraine Foundation. July 12, 2023. https://americanmigrainefoundation.org/resource-library/migraine-terms/

# Results: Lexicon Analysis Among People With Migraine Disease on Reddit




The most significant and meaningful shift in conversation focused on terms for a person with migraine disease

Migraine Personality, Migraineur, Migrainer, Migraine Person, Migraine-Type Person Person With Migraine Disease, Person Living With Migraine Disease

Four other categories of language exhibited a small, but significant, shift in lexicon post-2019

<sup>\*</sup>P<0.05; \*\*P<0.0001.

### Results: HCP Lexicon Analysis on X



- There were few social media posts by HCPs on X that used legacy language and/or CHAMPrecommended language
- Posts by HCPs revealed a small, but significant, shift in lexicon around terms for migraine disease

Migraine Headache, Migraines




Migraine Disease, Living With Migraine Disease

<sup>\*</sup>P<0.05.

# Methods: Sentiment Analysis of Migraine Treatments and Symptoms Pre- and Post-approval of CGRP-Targeting Therapies

#### **Data Collection**





### **Data Analysis**

- Sentiment scores were assigned to specific named entities within individual Reddit posts
- Distribution of scores assessed as percentile levels
  - Relatively strong negative (10th percentile)
  - Relatively strong positive (90th percentile)
- Score range:



# Results: Sentiment Analysis of Migraine Treatments and Symptoms Pre- and Post-approval of CGRP-Targeting Therapies


		Sentiment Sco	ores Pre- and Pos	st-2018		
Percentile	Relative Sentiment	Mean Pre-2018 ± SD	Mean Post-2018 ± SD	Delta of Mean	Effect Size	Adjusted <i>P</i> -Value
	All Sent	iment (CGRP– an	d Non–CGRP-Targe	eting Treatme	ents)	
10 <sup>th</sup>	Most Negative	-22.55 ± 4.66	-22.72 ± 2.30	-0.17	-0.05	1
Mean	Average	5.82 ± 2.36	6.67 ± 1.54	0.86	0.45	0.08
90 <sup>th</sup>	Most Positive	41.25 ± 4.41	46.53 ± 4.28	5.28	1.22	<0.0001(
		Non-CGRP-Targ	geting Treatment Se	entiment		
10 <sup>th</sup>	Most Negative	-24.33 ± 4.08	-27.89 ± 2.88	-3.57	-1.05	<0.0001(
Mean	Average	5.12 ± 2.61	4.74 ± 1.65	-0.38	-0.18	1
90 <sup>th</sup>	Most Positive	41.01 ± 4.71	43.15 ± 4.46	2.14	0.47	<0.05
		Sym	ptom Sentiment			
10 <sup>th</sup>	Most Negative	-16.64 ± 12.30	-21.30 ± 9.53	-4.66	-0.44	0.10
Mean	Average	-1.63 ± 14.43	$0.67 \pm 7.89$	2.30	0.21	0.99
90 <sup>th</sup>	Most Positive	12.62 ± 7.88	$22.04 \pm 9.75$	9.41	1.04	<0.0001

nt towards score for the nt increased

sentiment ing therapies nts, and the ntiment points

sentiment of migraine 9.41 points

# Results: Sentiment Analysis of Non-CGRP-Targeting vs CGRP-Targeting Treatments Post-2018



Sentiment Scores for Non–CGRP-Targeting vs CGRP-Targeting Treatments Post-2018								
Value	Relative Sentiment	Mean Non- CGRP ± SD	Mean CGRP ± SD	Delta of Mean	Effect Size	Adjusted <i>P</i> -Value		
Mean	Average	4.74 ± 1.65	8.40 ± 1.64	3.66	2.22	<0.0001		

The mean sentiment towards CGRPtargeting therapies was **3.66 points** higher than non–CGRP-targeting therapies post-2018

### **Key Takeaways**



#### **Lexicon Analysis**

- Self-identifying terms represented the largest shift in lexicon among people with migraine disease, reflecting a
  potential desire for patient-focused language
- HCP lexicon had minimal changes in response to the CHAMP/AMF language guidelines, with only one shift in terms for migraine disease noted, emphasizing the scientific and clinical focus of HCP language
- Due to the lack of notable changes in language by people with migraine disease and HCPs, this research
  highlights the need for greater dissemination of destigmatizing migraine language guidelines to engage more
  of the community



#### **Sentiment Analysis**

- There was increased positive sentiment towards migraine treatments since the introduction of CGRP-targeting therapies, suggesting a favorable perception of these treatments
- The growing positive sentiment associated with migraine treatments may suggest that the migraine community feels increasingly acknowledged and hopeful with the continued development of new treatments